Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Scaling up screening for viral hepatitis in Europe

A new toolkit on screening for chronic viral hepatitis seeks to raise awareness, improve knowledge and motivate public health professionals in Europe to take action. Knowledge and understanding of what works in screening for chronic hepatitis B/C has now been translated into practical and relevant tools, including videos and animations, to enable others to replicate successful screening programmes among at risk populations in their area.

Published
15 December 2014
From
Medical Xpress
Class Action Lawsuit Challenges Exorbitant Pricing of Gilead’s Hepatitis-C Drug Sovaldi

Gilead has been selling a twelve week regimen of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. This is significantly more than the original price projection for Sovaldi, and in sharp contrast to the prices at which the drug is being made available in other countries. Gilead recently announced its intention to make Sovaldi available in 91 developing countries at deeply discounted prices, and the drug is reportedly available in Egypt for 99% below the U.S. price. This obvious pricing paradox is under investigation by the Senate Finance Committee, which has questioned if the market for Sovaldi “is working efficiently and rationally,” and whether “payors of health care….can carry such a load.”

Published
12 December 2014
From
Chimicles & Tikellis press release
Philadelphia Agency Sues Gilead Over Price Of Hepatitis Drug

Philadelphia's transit agency has sued Gilead Sciences Inc., accusing the company of "price-gouging" on the sale of its $1,000-per-pill hepatitis C drug Sovaldi, the latest salvo in a battle between health-care payers and the pharmaceutical industry.

Published
11 December 2014
From
Nasdaq
Daclatasvir for hepatitis C: added benefit not proven

The German Institute for Quality and Efficiency in Health Care (IQWiG) has concluded that data for patients without cirrhosis of the liver who are infected with hepatitis C virus (HCV) genotype 1, and for patients with HCV genotype 4 are not suitable for proving an added benefit of Daklinza (daclatasvir).

Published
11 December 2014
From
German Institute for Quality and Efficiency in Health Care (IQWiG)
Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis

Difficult-to-treat hepatitis C patients with liver cirrhosis who were not cured with a prior course of first-generation HCV protease inhibitors had a sustained response rate of 96-97%

Published
10 December 2014
By
Liz Highleyman
Will AbbVie's 3-DA regimen prove a compelling competitor to Gilead's Harvoni?

Later this month, the FDA is expected to approve AbbVie's oral '3-DA' product - comprising Viekirax (ombitasvir/ paritaprevir/ ritonavir) plus Exviera (dasabuvir) - for the treatment of genotype 1 hepatitis C patients. European approval is expected to occur in early 2015 following a positive recommendation from a European Medicines Agency committee last month. Payers in the US are hoping that AbbVie will deliver festive cheer by announcing a notable 'sticker price' discount versus Gilead Sciences' Harvoni brand, which costs $94,500 for a 12-week supply.

Published
10 December 2014
From
Hepatitis C New Drugs
Pakistani Blood Transfusions Spreading Hepatitis, HIV: Official

Lax oversight of blood banks means about a fifth of patients in Pakistan who get regular transfusions have been infected with hepatitis, a top government health official said on Friday. Some also get HIV.

Published
09 December 2014
From
HepatitisCNewDrugs
European HIV response "falling behind" as Eastern European epidemic grows

HIV diagnoses have increased by 80% in the European region since 2004, and three quarters of new HIV diagnoses in the European region are occurring in Eastern

Published
05 December 2014
By
Keith Alcorn
Safer injecting practices would be better promoted by focusing on pleasure and practical concerns – not the risk of infection

Harm reduction interventions often fail to engage people who inject drugs because they over-emphasise infection and risk, Magdalena Harris of the London School of Hygiene and Tropical

Published
03 December 2014
By
Roger Pebody
Sofosbuvir/ledipasvir with ribavirin cures most people with hepatitis C recurrence after liver transplantation

An interferon-free regimen of sofosbuvir plus ledipasvir (Harvoni) taken with ribavirin for 12 or 24 weeks led to sustained virological response in nearly all HCV genotype 1patients with fibrosis

Published
02 December 2014
By
Liz Highleyman

Filter by country